Crispr Therapeutics (NASDAQ:CRSP) Earns Buy Rating from Wells Fargo & Co

Share on StockTwits

Wells Fargo & Co restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note released on Friday, AnalystRatings.com reports.

Several other equities analysts also recently weighed in on the stock. Roth Capital lifted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, November 19th. Piper Jaffray Companies reissued a buy rating and set a $104.00 target price on shares of Crispr Therapeutics in a report on Tuesday, November 26th. BidaskClub raised Crispr Therapeutics from a buy rating to a strong-buy rating in a report on Saturday, November 30th. Finally, Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research report on Monday, November 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Crispr Therapeutics currently has a consensus rating of Buy and a consensus target price of $69.54.

Shares of CRSP opened at $72.37 on Friday. The business has a 50-day moving average of $54.81 and a 200 day moving average of $47.38. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The firm has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, research analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.

In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth about $4,366,000. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the third quarter worth approximately $21,167,000. Granahan Investment Management Inc. MA lifted its stake in shares of Crispr Therapeutics by 8.3% in the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock worth $1,418,000 after buying an additional 2,655 shares in the last quarter. Barclays PLC grew its holdings in shares of Crispr Therapeutics by 42.7% during the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after buying an additional 4,151 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of Crispr Therapeutics by 18.0% during the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after buying an additional 1,491 shares during the last quarter. 49.82% of the stock is currently owned by hedge funds and other institutional investors.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What are earnings reports?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.